Xiaohui Suo
YOU?
Author Swipe
View article: Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) in elder or intensive chemotherapy ineligible patients with newly diagnosed acute myeloid leukemia
Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) in elder or intensive chemotherapy ineligible patients with newly diagnosed acute myeloid leukemia Open
View article: A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy
A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy Open
Although tyrosine kinase inhibitor (TKI) therapy has markedly improved the survival of people with chronic-phase chronic myeloid leukemia (CML), 20% to 30% of people still experienced therapy failure. Data from 1955 consecutive patients wi…
View article: Venetoclax combined with daunorubicin and cytarabine (2 + 6) in acute myeloid leukemia: Updated results of a phase II trial
Venetoclax combined with daunorubicin and cytarabine (2 + 6) in acute myeloid leukemia: Updated results of a phase II trial Open
Previous research has demonstrated that the combination of Venetoclax (Ven) and intensive chemotherapy (IC) enhances the complete response (CR) and minimal residual disease (MRD) negative rate in patients with de novo Acute Myeloid Leukemi…
View article: Assessment of prolonged proteasome inhibition through <scp>ixazomib‐based</scp> oral regimen on newly diagnosed and first‐relapsed multiple myeloma: A <scp>real‐world</scp> Chinese cohort study
Assessment of prolonged proteasome inhibition through <span>ixazomib‐based</span> oral regimen on newly diagnosed and first‐relapsed multiple myeloma: A <span>real‐world</span> Chinese cohort study Open
Objective To evaluate the effectiveness, safety, and convenience of in‐class transition (iCT) from intravenous bortezomib‐based induction to ixazomib‐based oral regimens. Methods This retrospective real‐world study was conducted in 16 Chin…
View article: B‐cell maturation antigen chimeric antigen receptor‐T therapy alleviated heart failure in patients with multiple myeloma
B‐cell maturation antigen chimeric antigen receptor‐T therapy alleviated heart failure in patients with multiple myeloma Open
Patients with multiple myeloma (MM) are likely to achieve poor therapeutic response when organs are involved. We produced anti‐B‐cell maturation antigen (BCMA) chimeric antigen receptor (CAR)‐T cells, which are in a trial for patients with…
View article: Anti‑BCMA CAR‑T cell immunotherapy for relapsed or refractory multiple myeloma
Anti‑BCMA CAR‑T cell immunotherapy for relapsed or refractory multiple myeloma Open
The present study aimed to study the efficacy and adverse effects of anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T (CAR-T) cell therapy in relapsed or refractory multiple myeloma. Patients were divided into three dose g…
View article: P507: SALVAGE THERAPY WITH VENETOCLAX IN COMBINATION WITH AZACITIDINE, HOMOHARRINGTONINE AND CYTARABINE IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
P507: SALVAGE THERAPY WITH VENETOCLAX IN COMBINATION WITH AZACITIDINE, HOMOHARRINGTONINE AND CYTARABINE IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA Open
Background: In recent years, the efficacy of acute myeloid leukemia (AML) has been improved, but the outcome of relapsed/refractory (R/R) AML patients is still poor. Traditional chemotherapy is not effective for these patients with complet…
View article: Venetoclax combined with daunorubicin and cytarabine (2 + 6) as induction treatment in adults with newly diagnosed acute myeloid leukemia: a phase 2, multicenter, single-arm trial
Venetoclax combined with daunorubicin and cytarabine (2 + 6) as induction treatment in adults with newly diagnosed acute myeloid leukemia: a phase 2, multicenter, single-arm trial Open